This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jang, I. K. Articles by Collen, D. Search for Related Content PubMed PubMed Citation Articles by Jang, I. K. Articles by Collen, D.

Circulation, Vol 81, 219-225, Copyright © 1990 by American Heart Association

ARTICLES

Prevention of platelet-rich arterial thrombosis by selective thrombin inhibition

IK Jang, HK Gold, AA Ziskind, RC Leinbach, JT Fallon and D Collen
Cardiac Unit, Massachusetts General Hospital, Boston 02114.

The effect of heparin and of the synthetic competitive thrombin inhibitor (2R,4R)-4-methyl-1-[N2-(3-methyl-1,2,3,4-tetrahydro-8- quinolinesulfon yl)-L-arginyl]-2-piperidinecarboxylic acid monohydrate (argatroban) on platelet-rich arterial thrombosis was studied in a rabbit model, consisting of a 4-6-mm everted ("inside-out") femoral arterial segment. Intravenous injection of heparin (200 units/kg) failed to prevent occlusion within 60 minutes in all 10 rabbits, whereas intravenous argatroban infusion at a rate of 100 or 200 micrograms/kg/min for 60 minutes, which prolonged the thrombin time more than fourfold, prevented thrombosis in nine of 13 rabbits (p = 0.002 vs. i.v. heparin). Intra-arterial infusion of 200 units/kg heparin over 60 minutes prevented occlusion in six of nine rabbits (p = 0.003 vs. i.v. heparin), whereas intra-arterial argatroban at a rate of 100 micrograms/kg/min for 60 minutes prevented thrombosis in all 10 rabbits (p = 0.00001 vs. i.v. heparin). Patency of femoral arterial segments was maintained after the end of the intra-arterial heparin and intravenous or intra-arterial argatroban infusion for up to 3 hours despite normalization of the thrombin time and partial thromboplastin time. Pathologic examination of the graft revealed that the inverted adventitial surface was covered by layers of platelets without platelet aggregation or fibrin deposition. These findings indicate that thrombin plays an important role in platelet-rich arterial thrombosis, and that the thrombogenic stimulus is rapidly attenuated by short-term infusion of the synthetic thrombin inhibitor. Selective thrombin inhibition can constitute an alternative approach to the prevention of arterial occlusion after angioplasty or thrombolytic therapy in patients with unstable coronary syndromes.

This article has been cited by other articles:

				C. V. Jackson, B. D. Bailey, and T. J. Shetler Pharmacological Profile of Recombinant, Human Activated Protein C (LY203638) in a Canine Model of Coronary Artery Thrombosis J. Pharmacol. Exp. Ther., December 1, 2000; 295(3): 967 - 971. [Abstract] [Full Text]

				I.-K. Jang, D. F. M. Brown, R. P. Giugliano, H. V. Anderson, D. Losordo, J. C. Nicolau, O. P. Dutra, O. Bazzino, V. M. Viamonte, R. Norbady, et al. A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with Novastan and TPA (MINT) study J. Am. Coll. Cardiol., June 1, 1999; 33(7): 1879 - 1885. [Abstract] [Full Text] [PDF]

				S. Ahmad, A. Ahsan, O. Iqbal, D. A. Hoppensteadt, B. E. Lewis, J. M. Walenga, and J. Fareed Pharmacokinetics and Pharmacodynamics of Argatroban as Studied by HPLC and Functional Methods: Implications in the Monitoring and Dosage-Optimizations in Cardiovascular Patients Clinical and Applied Thrombosis/Hemostasis, October 1, 1998; 4(4): 243 - 249. [Abstract] [PDF]

				M.-C. Chang, H.-K. Lin, H.-C. Peng, and T.-F. Huang Antithrombotic Effect of Crotalin, a Platelet Membrane Glycoprotein Ib Antagonist From Venom of Crotalus atrox Blood, March 1, 1998; 91(5): 1582 - 1589. [Abstract] [Full Text] [PDF]

				W. F. Baker JR Thrombosis and Hemostasis in Cardiology: Review of Pathophysiology and Clinical Practice (Part I) Clinical and Applied Thrombosis/Hemostasis, January 1, 1998; 4(1): 51 - 75. [Abstract] [PDF]

				H. D. White, P. E. Aylward, M. J. Frey, A. A. J. Adgey, R. Nair, W. S. Hillis, Y. Shalev, M. A. Brown, J. K. French, R. Collins, et al. Randomized, Double-blind Comparison of Hirulog Versus Heparin in Patients Receiving Streptokinase and Aspirin for Acute Myocardial Infarction (HERO) Circulation, October 7, 1997; 96(7): 2155 - 2161. [Abstract] [Full Text]

				U. Orvim, R. M. Barstad, G. P. Vlasuk, and K. S. Sakariassen Effect of Selective Factor Xa Inhibition on Arterial Thrombus Formation Triggered by Tissue Factor/Factor VIIa or Collagen in an Ex Vivo Model of Shear-Dependent Human Thrombogenesis Arterioscler Thromb Vasc Biol, December 1, 1995; 15(12): 2188 - 2194. [Abstract] [Full Text]

				J. Strony, A. Song, L. Rusterholtz, and B. Adelman Aurintricarboxylic Acid Prevents Acute Rethrombosis in a Canine Model of Arterial Thrombosis Arterioscler Thromb Vasc Biol, March 1, 1995; 15(3): 359 - 366. [Abstract] [Full Text]

				J. P. Carteaux, A. Gast, T. B. Tschopp, and S. Roux Activated Clotting Time as an Appropriate Test to Compare Heparin and Direct Thrombin Inhibitors Such as Hirudin or Ro 46-6240 in Experimental Arterial Thrombosis Circulation, March 1, 1995; 91(5): 1568 - 1574. [Abstract] [Full Text]

				J. S. Mruk, P. Zoldhelyi, M. W.I. Webster, M. Heras, D. E. Grill, D. R. Holmes Jr, V. Fuster, and J. H. Chesebro Does Antithrombotic Therapy Influence Residual Thrombus After Thrombolysis of Platelet-Rich Thrombus? : Effects of Recombinant Hirudin, Heparin, or Aspirin Circulation, February 15, 1995; 93(4): 792 - 799. [Abstract] [Full Text]

				M. Sobel Heparin-Induced Thrombocytopenia Perspectives in Vascular Surgery and Endovascular Therapy, January 1, 1992; 5(2): 1 - 27. [PDF]

				J. J. Popma and E. J. Topol Adjuncts to Thrombolysis for Myocardial Reperfusion Ann Intern Med, July 1, 1991; 115(1): 34 - 44. [Abstract] [PDF]